Revvity, Inc.
NYSE:RVTYMedical - Diagnostics & Research
-$3.40 today
- Market cap
- $17.02B
- Beta
- 1.11
- P/E (TTM)
- 45.4
- EPS (TTM)
- $2.15
- Dividend yield
- 0.29%
Volume 1.09M
Average 1.27M
RVTY Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Revvity, Inc.NYSE: RVTY
Research & Development · Q2 FY2026 · quarter ended Jul 2026
Research & development dips below year-ago levels
Q2 FY2026 research & development of $48.97M fell 8.1% year over year, behind the +5.2% change in trailing-twelve-month research & development. Sequentially, it fell 15.4% from the prior quarter. Over 3 fiscal years it compounded at -0.9% a year.
Context
- Research & development amounted to 7.6% of revenue in FY2025, up 0.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -8.1% toward the trailing-twelve-month pace of +5.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 215.84M USD
- Year-over-year change
- +9.7%
- 4-year CAGR
- +1.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 215.84M | +9.7% |
| FY2024 | 2024-12-29 | 196.84M | -9.1% |
| FY2023 | 2023-12-31 | 216.58M | -2.3% |
| FY2022 | 2022-12-31 | 221.62M | +10.6% |
| FY2021 | 2021-12-31 | 200.34M | — |
Research & Development vs competitors
How RVTY compares with its peers on the latest reported figures
- RVTY's LTM Jul 2026 research & development of $215.83M is the 6th highest of the 11 companies compared; the peer median is $234.55M.
- Its year-over-year change of +5.2% is the 5th highest of 10, against a peer median of +4.2%.
- Research & development amounts to 7.4% of revenue for RVTY, versus a peer median of 6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.67B | +4.2% | +1.5% | 6.5% | |
| LTM Sep 2026 | $1.41B | -0.7% | -1.7% | 3.0% | |
| LTM Jul 2026 | $485M | +8.5% | -0.9% | 6.6% | |
| LTM Jul 2026 | $321.75M | +71.7% | +3.5% | 6.9% | |
| LTM Jun 2026 | $261.1M | -14.3% | +0.0% | 10.1% | |
| LTM Jul 2026 | $215.83M | +5.2% | -0.9% | 7.4% | |
| LTM Jun 2026 | $208.01M | +7.9% | +4.0% | 5.0% | |
| LTM Jun 2026 | $194.67M | +5.5% | -0.4% | 9.3% | |
| LTM Sep 2026 | $96.87M | -3.0% | +0.8% | 7.9% | |
| LTM Mar 2026 | $20.31M | +4.0% | -0.3% | 8.2% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RVTY) | $234.55M | +4.2% | +0.0% | 6.8% | |
Competitors are the stored peer set for RVTY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.83B | 3.31B | 2.75B | 2.76B | 2.86B |
| Cost of Revenue | 1.55B | 1.55B | 1.43B | 1.43B | 1.34B |
| Gross Profit | 2.28B | 1.76B | 1.32B | 1.32B | 1.52B |
| Gross Margin | 59.6% | 53.2% | 48.1% | 48.0% | 53.1% |
| Research & Development | 200.34M | 221.62M | 216.58M | 196.84M | 215.84M |
| Selling, General & Admin | 741.61M | 757.99M | 706.12M | 715.3M | 945.29M |
| Operating Expenses | 941.95M | 979.61M | 922.7M | 912.14M | 1.16B |
| Depreciation & Amortization | 311.44M | 427M | 431.77M | 427.85M | 405.34M |
| EBITDA | 1.62B | 1.18B | 713.56M | 840.25M | 765.8M |
| EBITDA Margin | 42.2% | 35.7% | 25.9% | 30.5% | 26.8% |
| Operating Income | 1.34B | 781.12M | 399.49M | 410.52M | 356.64M |
| Operating Margin | 35.0% | 23.6% | 14.5% | 14.9% | 12.5% |
| Interest Income | 2.24M | 3.59M | 72.13M | 73.19M | 31.1M |
| Interest Expense | 102.13M | 103.96M | 98.81M | 96.28M | 92.19M |
| Other Income / Expenses | (136.42M) | (129.29M) | (216.52M) | (94.39M) | (88.36M) |
| Income Before Tax | 1.2B | 651.84M | 182.98M | 316.13M | 268.28M |
| Pre-Tax Margin | 31.4% | 19.7% | 6.7% | 11.5% | 9.4% |
| Income Tax Expense | 314.15M | 139.16M | 3.47M | 33.06M | 25.8M |
| Net Income | 943.16M | 569.18M | (118.38M) | 295.83M | 241.68M |
| Net Margin | 24.6% | 17.2% | -4.3% | 10.7% | 8.5% |
| EPS (Basic) | 8.12 | 4.51 | (0.95) | 2.41 | 2.08 |
| EPS (Diluted) | 8.08 | 4.50 | (0.95) | 2.41 | 2.08 |
| Weighted Avg Shares | 116.17M | 126.16M | 124.7M | 122.76M | 113.21M |
| Weighted Avg Shares (Diluted) | 116.67M | 126.43M | 124.81M | 122.82M | 113.21M |
Revvity, Inc.
NYSE:RVTY
Intrinsic Alpha fair value
Locked
Current Price
$152.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.